Premium
Is immune checkpoint inhibition part of standard therapy for stage III non‐small cell lung cancer?
Author(s) -
Patel Jyoti D.,
Chmura Steven J.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31557
Subject(s) - durvalumab , medicine , standard of care , oncology , stage (stratigraphy) , radiation therapy , placebo , lung cancer , toxicity , clinical trial , systemic therapy , cancer , immunotherapy , nivolumab , pathology , paleontology , alternative medicine , biology , breast cancer
Decades of clinical trials investigating radiation dose modification and systemic therapy intensification have failed to improve outcomes in patients with unresectable stage III NSCLC. Treatment with durvalumab after chemoradiation improves progression free survival three‐fold compared to placebo with minimal increases in toxicity and represents a new standard of care for these patients.